Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders

Karim, Nasiara; Abdelhalim, Heba; Gavande, Navnath; Khan, Imran; Khan, Haroon

doi:https://doi.org/10.1155/2018/3056847

Evidence-Based Complementary and Alternative Medicine

On this page

Acknowledgments References Copyright Related Articles

Special Issue

Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders

View this Special Issue

Editorial | Open Access

Volume 2018 | Article ID 3056847 | https://doi.org/10.1155/2018/3056847

Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders

Nasiara Karim,¹Heba Abdelhalim,²Navnath Gavande,³Imran Khan,⁴and Haroon Khan⁵

Received04 Mar 2018

Accepted04 Mar 2018

Published03 Apr 2018

Neurological disorders are common and represent a major public health problem. Neurological disorders include dementia, epilepsy, headache disorders, multiple sclerosis, and neuroinfections, neurological disorders associated with malnutrition, pain associated with neurological disorders, Parkinson’s disease, stroke, and traumatic brain injuries. There are approximately 450 million of world population suffering from these mental disorders [1]. For example, 50 million people have epilepsy and this number is increasing day by day [2]. The number of people suffering from dementia and memory disorders is projected to be doubled every 20 years. Currently, 322 million people suffer from major depression [3] and this number is on the rise. Neurological disorders constitute over 6% of the global burden of disease [4]. This burden is especially high in many low- and middle-income countries.

Considerable efforts have been made in recent decades to discover substances which can help prevent these serious neurological disorders. Natural products are small molecules found in divergent natural sources. They possess a coveted position in the treatment of all human illnesses including neurological disorders. They are believed to be the single most important source of drug leads [5]. The importance of plant derived natural products for the treatment of neurological disorders is evident by the fact that most of the earlier drugs used for the treatment of neurological disorders were derived from plants including opioids alkaloids [6], galantamine [7], and anticholinesterases like physostigmine and neostigmine [8]. During the last decade out of total 26 natural drugs approved, 7 were for the treatment of neurological disorders, out of which 3 were for Parkinson’s disease [9].

This special issue focuses on original contributions for natural products being useful in various neurological disorders including anxiety, depression, stroke, epilepsy, and other CNS disorders and their possible mechanisms of action.

Acknowledgments

We are grateful to all authors for their valuable contributions to this special issue. We are also thankful to the reviewers for their valuable suggestions and constructive comments to improve the quality of the published manuscripts. We are also grateful to this journal for inviting us to participate in this special issue.

Nasiara Karim
Heba Abdelhalim
Navnath Gavande
Imran Khan
Haroon Khan

References

R. C. Kessler, S. Aguilar-Gaxiola, J. Alonso et al., “The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys,” Epidemiologia e Psichiatria Sociale, vol. 18, no. 1, pp. 23–33, 2009.
View at: Publisher Site | Google Scholar
A. Paul, D. Adeloye, R. George-Carey, I. Kolčić, L. Grant, and K. Y. Chan, “An estimate of the prevalence of epilepsy in Sub–Saharan Africa: A systematic analysis,” Journal of Global Health, vol. 2, no. 2, article 020405, 2012.
View at: Publisher Site | Google Scholar
S. S. Clevenger, D. Malhotra, J. Dang, B. Vanle, and W. W. IsHak, “The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder,” Therapeutic Advances in Psychopharmacology, vol. 8, no. 1, pp. 49–58, 2017.
View at: Publisher Site | Google Scholar
H. A. Whiteford, A. J. Ferrari, L. Degenhardt, V. Feigin, and T. Vos, “The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010,” PLoS ONE, vol. 10, no. 2, Article ID e0116820, 2015.
View at: Publisher Site | Google Scholar
H. Nasri, A. Baradaran, H. Shirzad, and M. Rafieian-Kopaei, “New concepts in nutraceuticals as alternative for pharmaceuticals,” International Journal of Preventive Medicine, vol. 5, no. 12, pp. 1487–1499, 2014.
View at: Google Scholar
H. Pathan and J. Williams, “Basic opioid pharmacology: an update,” British Journal of Pain, vol. 6, no. 1, pp. 11–16, 2012.
View at: Publisher Site | Google Scholar
J. Olin and L. Schneider, “Galantamine for Alzheimer's disease,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD001747, 2002.
View at: Google Scholar
M. B. Colovic, D. Z. Krstic, T. D. Lazarevic-Pasti, A. M. Bondzic, and V. M. Vasic, “Acetylcholinesterase inhibitors: pharmacology and toxicology,” Current Neuropharmacology, vol. 11, no. 3, pp. 315–335, 2013.
View at: Google Scholar
M.-C. Boll, M. Alcaraz-Zubeldia, and C. Rios, “Medical management of parkinson's disease: focus on neuroprotection,” Current Neuropharmacology, vol. 9, no. 2, pp. 350–359, 2011.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2018 Nasiara Karim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

2652

Downloads

1095

Citations